{"id":"W2612879952","doi":"10.1093/rheumatology/kex174","title":"Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA","year":2017,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Genentech; Astellas Pharma; Chugai Pharmaceutical; Celltrion; Dermira; Gilead Sciences; Ablynx; UCB Pharma; Zynerba Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Certolizumab pegol; BASDAI; BASFI; Internal medicine; Adverse effect; Placebo; Physical therapy; Axial spondyloarthritis; Ankylosing spondylitis; Arthritis; Etanercept; Rheumatoid arthritis; Sacroiliitis; Psoriatic arthritis; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006731608,0.0003467774,0.001186586,0.000147192,0.0002737728,0.00005117327,0.0001678977,0.000168506,0.0002435814],"category_scores_gemma":[0.0007300379,0.0002900251,0.000215507,0.00008475161,0.0002503389,0.000162145,0.0003404553,0.0002036478,0.00001593833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008928689,"about_ca_system_score_gemma":0.00007834769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002219561,"about_ca_topic_score_gemma":0.0008238751,"domain_scores_codex":[0.997816,0.00005724583,0.0007304716,0.0005114948,0.0004183091,0.0004665165],"domain_scores_gemma":[0.9981603,0.0001912068,0.0003981417,0.0009463358,0.0001242118,0.0001798069],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001928648,0.0005391535,0.9551719,0.00002746986,0.0005533894,0.003078965,0.0009216238,2.996807e-7,0.0001106628,0.0001694034,0.00009771113,0.0374008],"study_design_scores_gemma":[0.02934036,0.0005416423,0.9663001,0.0001710742,0.0001933365,0.00007860705,0.000870129,0.000007403228,0.0001786223,0.0001599041,0.001916172,0.0002426312],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913252,0.001265159,0.000003144974,0.002495646,0.0003622954,0.0008688114,0.0002371287,0.00005453929,0.003388085],"genre_scores_gemma":[0.9984602,0.0005794408,0.0003047994,0.00009465745,0.00005780064,0.00003088768,0.0001084168,0.00004198783,0.0003218223],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03715817,"threshold_uncertainty_score":0.9999552,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01707595078920577,"score_gpt":0.2762103777811224,"score_spread":0.2591344269919166,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}